Protagonist Therapeutics, Inc. (PTGX) Shareholders & Insider Trades
Protagonist Therapeutics shareholders at a glance
The largest holder of Protagonist Therapeutics stock is BlackRock Advisors LLC, with 9.7 million shares (15.06% of the company), worth about $1.44 billion as of September 25, 2026. The 10 largest holders together own 65.7%.
In Q2 2026, 361 institutional holdings reports listed shares worth $9.35 billion.
Insiders reported 80 transactions in the last two years: 33 sales worth $65.21 million and no purchases. The newest one on file is from May 12, 2026 (Patel Dinesh V, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 12, 2026.
Protagonist Therapeutics, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Protagonist Therapeutics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 9.7 million | 15.06% | $1.4B |
| Farallon Capital Management LLC | 6.3 million | 9.81% | $938.0M |
| RTW Investments LP | 5.1 million | 7.82% | $748.0M |
| Vanguard Portfolio Management LLC | 3.6 million | 5.61% | $536.0M |
| Wellington Trust Co., NA | 3.4 million | 5.28% | $505.0M |
| UBS Financial Services, Inc. | 3.3 million | 5.15% | $492.0M |
| State Street Corporation | 3.3 million | 5.13% | $491.0M |
| Vanguard Capital Management LLC | 2.9 million | 4.41% | $422.0M |
| Johnson & Johnson Innovation - JJDC, Inc. | 2.4 million | 3.79% | $362.0M |
| Invesco Advisers, Inc. | 2.3 million | 3.62% | $346.0M |
As of September 25, 2026.
Protagonist Therapeutics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 361 | – | $9.4B |
| Q1 2026 | 339 | – | $8.3B |
| Q4 2025 | 338 | – | $6.2B |
| Q3 2025 | 286 | – | $4.7B |
| Q2 2025 | 290 | 71.5 million | $4.0B |
| Q1 2025 | 299 | 65.4 million | $3.2B |
| Q4 2024 | 255 | 63.8 million | $2.5B |
| Q3 2024 | 253 | 62.3 million | $2.8B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Protagonist Therapeutics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Patel Dinesh V | May 12, 2026 | Chief Executive Officer | Sale at price 100.12 per share. | $7.5M |
| Patel Dinesh V | May 12, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 21.58 per share. | $1.6M |
| Giraudo Bryan M. | May 8, 2026 | Director | Sale at price 100.00 - 100.14 per share. | $5.9M |
| Giraudo Bryan M. | May 7, 2026 | Director | Conversion of Exercise of derivative security at price 6.45 - 6.98 per share. | $238,560 |
| Patel Dinesh V | Apr 23, 2026 | Chief Executive Officer | Stock Gift at price 0.00 per share. | – |
| Ali Asif | Apr 20, 2026 | Chief Financial Officer | Sale at price 105.47 per share. | $184,572 |
| Selick Harold E | Mar 26, 2026 | Director | Sale at price 105.00 per share. | $2.5M |
| Molina Arturo Md | Mar 26, 2026 | Officer | Sale at price 104.79 per share. | $1.6M |
| Ali Asif | Mar 26, 2026 | Chief Financial Officer | Sale at price 104.24 per share. | $2.6M |
| Ali Asif | Mar 26, 2026 | Chief Financial Officer | Conversion of Exercise of derivative security at price 12.17 - 19.19 per share. | $438,280 |
| Selick Harold E | Mar 26, 2026 | Director | Conversion of Exercise of derivative security at price 12.88 per share. | $309,120 |
| Molina Arturo Md | Mar 26, 2026 | Officer | Conversion of Exercise of derivative security at price 8.04 per share. | $120,600 |
Newest 12 of 80 insider transactions in the last two years.
Questions and answers
Who owns the most Protagonist Therapeutics stock?
BlackRock Advisors LLC, with 15.06% of the company (as of September 25, 2026). Next: Farallon Capital Management LLC (9.81%) and RTW Investments LP (7.82%).
How many institutions own Protagonist Therapeutics stock?
361 institutional holdings reports listed Protagonist Therapeutics shares in Q2 2026 worth $9.35 billion.
Are Protagonist Therapeutics insiders buying or selling the stock?
In the last two years insiders reported 33 sales and no purchases (80 transactions in all); the newest on file is from May 12, 2026.
